Reimbursement

Coding and Reimbursement: US Healthcare Providers Only

Updated: April 27, 2022

Payer guidelines are subject to change without notice.

2022 Billing and Coding Guide with Sample Claim Forms

iStent inject® W

Approved Indications

The iStent inject® W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.

Coding Options

CPT®1 Codes

CPT Code Descriptor Modifiers
66989

Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic development stage; with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more.

-LT (left side), or 
-RT (right side)

66991

Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more.

-LT (left side), or 
-RT (right side)

HCPCS Codes

Hospital outpatient departments (HOPDs) must report all items and services using the correct HCPCS codes. Failure to report the HCPCS code may result in incorrect payment. Some ASC claims to commercial payers may also require the inclusion of a HCPCS code. ASCs should review their payer provider contracts for guidance.

HCPCS Code Description Revenue Code
C1783 Ocular implant; aqueous drainage assist device 0278; other implants
L8612 Aqueous shunt 0278; other implants

Diagnosis Codes

In all cases, it is ultimately the responsibility of the provider to report the ICD-10-CM diagnosis code that most accurately describes the patient’s condition.

The following possible ICD-10-CM diagnosis codes describe conditions that are consistent with the FDA labeled indication for iStent inject® W.

  • H40.1111 – Primary Open Angle Glaucoma, Right Eye, Mild Stage
  • H40.1112 – Primary Open Angle Glaucoma, Right Eye, Moderate Stage
  • H40.1121 – Primary Open Angle Glaucoma, Left Eye, Mild Stage
  • H40.1122 – Primary Open Angle Glaucoma, Left Eye, Moderate Stage
  • H40.1131 – Primary Open Angle Glaucoma, Bilateral, Mild Stage
  • H40.1132 – Primary Open Angle Glaucoma, Bilateral, Moderate Stage

Request the iStent inject® W posters
presented at ARVO 2021

Five posters presented at ARVO 2021 highlight the efficacy and safety of the iStent platform as compared to other procedures.

Request Clinical Information

Claims Submission Process

Each provider is responsible for ensuring all claims are accurately coded and submitted on a timely basis. Fully documented claims helps to minimize delay in proper reimbursement.

Coverage Highlights

iStent inject® W is broadly covered by both Medicare Administrative Contractors (MACs) as well as the majority of commercial payers.

Private payers may require a prior authorization before performing the iStent inject® W procedure.

Please check with your local Glaukos Regional Business Manager or Field Reimbursement Director for the latest updates on coverage in your area.

2022 National Average Unadjusted Medicare Payment

Private payers each employ their own methodology to determine payment amounts for services based on the CPT, ICD-10 and HCPCS codes billed on the claim and payment will be contingent upon the contractual agreement.

Facility billing departments should check the service contracts with individual private payers or contact each payer directly to verify the applicable reimbursement methodologies and/or amounts for the iStent inject® W implantation, the associated cataract procedure and for the iStent inject® W device itself. All HOPDs must include the iStent inject® W device on their claim forms to payers in order to capture the full cost of providing the service.

While many commercial payers will package the device reimbursement with the surgical facility payment for 66989/66991, some commercial payer claims in the Ambulatory Surgery Center setting may pay a carve-out for the iStent inject® W implant. A review of the specific payer’s requirement is recommended.

CPT Code Descriptor Physician
Payment*
Ambulatory
Surgical
Center (ASC)
Payment
Ambulatory
Payment
Classification
(APC)
Assignment
Hospital
Outpatient
Department
(HOPD) Payment

66989

Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic development stage; with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more

$856

$3245

New
Technology
APC1563

$4251

66991

Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more

$683

$3245

New
Technology
APC1563

$4251

iPath360 logo

iPath360 is available to assist iStent inject® W providers with coding, billing, and reimbursement questions and to provide additional support, including:

  • Prior authorization guidance
  • Letter templates
  • General coding and billing recommendations
  • Assistance with denied claims
  • Guidance for commercial contracting issues

To engage with iPath360, please call (844) 528-3311 or email us at support@ipath360.net


Glaukos provides this coding guide for informational purposes only and it is subject to change without notice. This guide is not an affirmative instruction as to which codes and modifiers to use for a particular service, supply, procedure or treatment and does not constitute advice regarding coding, coverage, or payment for Glaukos products. It is the responsibility of providers, physicians and suppliers to determine and submit appropriate codes, charges and modifiers for products, services, supplies, procedures, or treatment furnished or rendered. Providers, physicians and suppliers should contact their third-party payers for specific and current information on their coding, coverage, and payment policies. For further detailed product information, including indications for use, contraindications, effects, precautions and warnings, please consult the product’s Instructions for Use (IFU) prior to use. The information provided herein is without any other warranty or guarantee of any kind, expressed or implied, as to completeness, accuracy, or otherwise. This information is intended only to help estimate Medicare payment rates and product costs in the hospital outpatient department setting. All rates shown are national average Medicare rates and have not been adjusted for geographic variations in payment or other factors, such as sequestration.

  1. CPT is a registered trademark of the American Medical Association (AMA). Copyright 2022 AMA. All rights reserved.
  2. * Listed payment amounts are Medicare national average rates that are not adjusted (such as for locality or sequestration). The rates are from the 2022 National Physician Fee Schedule Relative Value File January Release, available at: https://www.cms.gov/files/zip/rvu22a.zip.
  3. Listed payment amounts are Medicare national average rates that are not adjusted (such as for locality or sequestration). The rates are from the January 2022 Addendum AA – ASC Covered Surgical Procedures for CY 2022, available at: https://www.cms.gov/license/ama?file=/files/zip/january-2022-asc-approved-hcpcs-code-and-payment-rates-updated-01122022.zip.
  4. https://www.federalregister.gov/documents/2022/01/13/2022-00573/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment.
  5. Listed payment amounts are Medicare national average rates that are not adjusted (such as for locality or sequestration). For procedures assigned to a new technology APC, such as CPT codes 66989 and 66991, Medicare payment is made even if included on a claim with a procedure assigned to a comprehensive APC. 83 Fed. Reg. 58818, 58847 (Nov. 21, 2018). The rates are from the 2022 Correction Notice OPPS Addendum B, available at https://www.cms.gov/medicaremedicarefee-service-paymenthospitaloutpatientppshospital-outpatient-regulations-and-notices/cms-1753-cn.

iStent inject® W Important Safety Information

Indication for Use

The iStent inject® W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.

Contraindications

The iStent inject® W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

Warnings

Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

MRI Information

The iStent inject® W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

Precautions

The surgeon should monitor the patient postoperatively for proper maintenance of IOP. The safety and effectiveness of the iStent inject® W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated IOP > 24 mmHg or unmedicated IOP < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.

Adverse Events

Common postoperative adverse events reported in the iStent inject® randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject® vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).

Caution

Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.